Clinical trials: Contrast Agent
Patients With Intraosseous Vascular Access Requiring Computed Tomography (CT) Exam
Observational Study of CT Dye Administration Through the Intraosseous Vascular Access Route
An observational study to determine the safety and effectiveness of Intraosseous (IO) vascular access for delivery of contrast dye for Computed Tomography (CT) examination.
- Trial name
- NCT01531686
- Testing
- Intraosseous delivery of CT contrast dye
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vidacare Corporation
Coronary Artery Disease, Healthy
Evaluation and Optimization of PB127 Myocardial Perfusion Echocardiography on Ultrasound Systems
The purpose of this clinical trial is to evaluate various commercially available ultrasound systems and to identify imaging parameters to be used with these systems (along with the contrast agent PB127) as well as to further…
- Trial name
- NCT00487903
- Testing
- PB127 for Injectable Suspension
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Point Biomedical
Cancer, Lung, Perfusion Computed Tomography Target Lesion
DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria
DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria. 1. Rationale of the clinical investigation For the evaluation of response to anti-tumoral therapy in thoracic…
- Conditions
- Cancer, Lung, Perfusion Computed Tomography Target Lesion, Cancer Liver, Metastatic Lung Cancer
- Trial name
- NCT04708483
- Testing
- Extra DCE-CT scan
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Hyperfusion
Healthy
A Healthy Volunteer Trial Investigating MR-enterography Image Quality of Lumentin® 44
A healthy volunteer, open, PoC single center trial investigating a new oral contrast agent for use in combination of MR examination of the abdomen and pelvis.
- Trial name
- NCT05781490
- Testing
- Lumentin® 44 Powder for oral foam
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Lument AB
Healthy, Coronary Artery Disease
Dose Finding Study of PB127 Ultrasound Contrast Agent in Healthy Volunteers and Patients With Coronary Artery Disease
The purpose of this study is to determine the dose of PB127 for detection and/or exclusion of coronary artery disease when used with cardiac ultrasound. This study also evaluates the safety of PB127.
- Trial name
- NCT00584818
- Testing
- PB127 for Injectable Suspension
- Where
- 16 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Point Biomedical
Neoplastic CNS Lesions
Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.
Study to compare of two contrast agents in imaging brain lesions.
- Trial name
- NCT00764387
- Testing
- Gadovist® (Gadobutrol, BAY86-4875), Dotarem
- Where
- 12 sites in Italy
- Volunteers
- 166 people
- Sponsor
- Bayer
Stroke, Ischemic, Stroke Hemorrhagic
Study on the Performance of a Machine Learning Algorithm Recognizing and Triaging Large Vessel Occlusions Using Non-contrast CT Scans
The goal of this prospective observational study is to assess the effectiveness and performance of Methinks AI stroke imaging software platform in acute Code Stroke patients, and as a comparator to study sites utilizing existing…
- Conditions
- Stroke, Ischemic, Stroke Hemorrhagic, Stroke, Acute, Brain Ischemia
- Trial name
- SMART-LVO (NCT06216457)
- Testing
- AI software for Stroke
- Volunteers
- 5,000 people
- Sponsor
- Methinks Software SL
Healthy
A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)
Pain is a significant issue and there is a need for better treatments for pain management. Local changes in skin blood flow can be used as an indicator of pain in the body.
- Trial name
- NCT06809569
- Testing
- Allyl Isothiocyanate (AITC), Capsaicin, Vehicle for AITC
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Age Related Cataracts
The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract
The study objectives were: To evaluate the efficacy of EDTA 1.3% and 2.6% ophthalmic solution (C-KAD) in improving visual function as assessed by contrast sensitivity; To evaluate the safety and tolerability of two doses of EDTA…
- Trial name
- NCT06365762
- Testing
- EDTA Ophthalmic Solution 2.6%, EDTA Ophthalmic Solution 1.3%
- Where
- 6 sites in United States
- Volunteers
- 111 people
- Sponsor
- Livionex Inc.
Magnetic Resonance Imaging
Contrast-enhanced MRI in Children 2 Months to <2 Years
The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to < 2 years of age
- Trial name
- NCT00937391
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-6661)
- Where
- 13 sites in United States, Germany
- Volunteers
- 54 people
- Sponsor
- Bayer
Coronary Angiography
DyeVert System RCT
The purpose of this study is to evaluate the amount of contrast media (CM) saved using the DyeVert system in diagnostic angiographic procedures compared to a control group.
- Trial name
- NCT02752802
- Testing
- Diagnostic Coronary Angiogram
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Osprey Medical, Inc
Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)
Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI).
- Trial name
- Quanti OBR (NCT05915728)
- Testing
- Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine
- Where
- 85 sites in United States, Argentina and 14 more
- Volunteers
- 410 people
- Sponsor
- Bayer
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF
This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure…
- Trial name
- NCT00156780
- Testing
- AI-700
- Where
- United States
- Sponsor
- Acusphere
Magnetic Resonance Imaging (MRI)
Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination
The purpose of this study is to prospectively collect data on the pattern of use for gadolinium-based contrast agents (GBCAs) in real-life setting with special reference to Clariscan after its commercial launch in Europe and in…
- Trial name
- NCT03455283
- Testing
- Clariscan, Gadolinium-Based Contrast Agents
- Where
- 2 sites in Germany, Norway
- Volunteers
- 2,118 people
- Sponsor
- GE Healthcare
Liver Lesions
An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging
The purpose of this study is to compare the efficacy of Sonazoid™ and SonoVue® in participants with focal liver lesions (FLLs), by comparing pre-and post-contrast ultrasound examination findings with regard to various aspects of…
- Trial name
- NCT03335566
- Testing
- Sonazoid™, SonoVue®
- Where
- 18 sites in China, South Korea and 1 more
- Volunteers
- 424 people
- Sponsor
- GE Healthcare
Computed Tomography
Study to Test the Usability of a New Injector to Administer Contrast Media Into Humans for Diagnostic Purposes
This study investigates if a new medical device, which injects contrast media and flushing solution into humans to increase the visibility of images taken of the human body for diagnostic purposes, is easier to handle, quicker…
- Trial name
- PERCENT (NCT03875469)
- Testing
- Centargo injector (BPI 1000045), Stellant MP injector
- Where
- 2 sites in Australia, Netherlands
- Volunteers
- 425 people
- Sponsor
- Bayer
Magnetic Resonance Imaging
Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects
Study Objectives Primary: To determine MTD and dose limiting toxicities (DLTs) of IOP magnetic resonance imaging (MRI) contrast agent in healthy subjects. Secondary: 1.
- Trial name
- NCT02744248
- Testing
- IOP Injection, 0.9% normal saline
- Where
- Taiwan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- MegaPro Biomedical Co. Ltd.
Contrast-enhanced MRI With Dotarem
Post-marketing Surveillance Study for Evaluation of Dotarem Safety
Guerbet conducted a non-interventional post-marketing surveillance study on its Magnetic Resonance Imaging (MRI) contrast agent Dotarem (gadoteric acid/gadoterate meglumine).
- Trial name
- NCT03048006
- Testing
- MRI with Dotarem
- Volunteers
- 44,456 people, healthy volunteers welcome
- Sponsor
- Guerbet
Carotid, Aortic, Renal or Peripheral Artery Disease
Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries
To compare two gadolinium contrast agents in terms of global paired diagnostic preference (primary endpoint) for the assessment of contrast-enhanced MR Angiography of the carotid, renal/abdominal and peripheral arteries
- Trial name
- VALUE (NCT01260636)
- Testing
- Gadobenate Dimeglumine, Gadopentetate Dimeglumine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Bracco Diagnostics, Inc
Central Nervous System Indication, Pediatric Patients
Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI
This is a pharmacokinetics (PK), open-label, uncontrolled, multicenter phase II trial with age-staggered approach. The primary objective is to evaluate the PK profile of gadopiclenol in plasma following single IV injection of…
- Conditions
- Central Nervous System Indication, Pediatric Patients, Body Indication
- Trial name
- NCT03749252
- Testing
- P03277
- Where
- 16 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 80 people
- Sponsor
- Guerbet